Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24005.X
G. Bubley
{"title":"Antisense TRPM‐2 Oligodeoxynucleotides Chemosensitize Human Androgen Independent PC‐3 Prostate Cancer Cells both In Vitro and In Vivo.","authors":"G. Bubley","doi":"10.1046/J.1525-1411.2000.24005.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24005.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90767576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24005-6.X
Y. Ko
{"title":"Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination with High‐Dose Three Dimensional Conformal Radiotherapy for Patients with Locally Advanced Prostate Cancer.","authors":"Y. Ko","doi":"10.1046/J.1525-1411.2000.24005-6.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24005-6.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82006414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.23009.X
X. Kong, L. Zeng, Yong Yang, T. Xia, F. Gu, Y. Guo, Chung-Shuh Lee
The goal of this study is to characterize stromal nodules in benign prostatic hyperplasia (BPH) in a Chinese population. BPH specimens were obtained by superpubic enucleation. Immunohistochemical staining for vimentin, muscle actin (HHF35), and smooth muscle actin (1A4) was conducted in serial sections of 55 consecutive stromal nodules of BPH specimens. The simplest stromal nodules were undifferentiated nodules that contained vimentin-negative and smooth muscle actin-negative cells. These cells were designated as undifferentiated mesenchymal cells. Immunohistochemical staining identified two cell types. Smooth muscle cells contained smooth muscle actin and vimentin, while fibrocytes contained vimentin but not smooth muscle actin. Fibrous nodules contained fibrocytes. Two more types of stromal nodules were fibromuscular nodules, which contained mixtures of fibrocytes and smooth muscle cells, and muscular nodules, which contained only smooth muscle cells. Of 55 stromal nodules, 11 (20%) were undifferentiated, 5 (9%) were fibrous, 37 (67%) were fibromuscular, and 2 (4%) were muscular.
{"title":"Immunohistochemical Characterization of Stromal Nodules in Benign Prostatic Hyperplasia","authors":"X. Kong, L. Zeng, Yong Yang, T. Xia, F. Gu, Y. Guo, Chung-Shuh Lee","doi":"10.1046/J.1525-1411.2000.23009.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.23009.X","url":null,"abstract":"The goal of this study is to characterize stromal nodules in benign prostatic hyperplasia (BPH) in a Chinese population. BPH specimens were obtained by superpubic enucleation. Immunohistochemical staining for vimentin, muscle actin (HHF35), and smooth muscle actin (1A4) was conducted in serial sections of 55 consecutive stromal nodules of BPH specimens. The simplest stromal nodules were undifferentiated nodules that contained vimentin-negative and smooth muscle actin-negative cells. These cells were designated as undifferentiated mesenchymal cells. Immunohistochemical staining identified two cell types. Smooth muscle cells contained smooth muscle actin and vimentin, while fibrocytes contained vimentin but not smooth muscle actin. Fibrous nodules contained fibrocytes. Two more types of stromal nodules were fibromuscular nodules, which contained mixtures of fibrocytes and smooth muscle cells, and muscular nodules, which contained only smooth muscle cells. Of 55 stromal nodules, 11 (20%) were undifferentiated, 5 (9%) were fibrous, 37 (67%) were fibromuscular, and 2 (4%) were muscular.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"22 1","pages":"199-204"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74619059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24005-5.X
Y. Ko
{"title":"Management of a Positive Surgical Margin After Radical Prostatectomy: Decision Analysis.","authors":"Y. Ko","doi":"10.1046/J.1525-1411.2000.24005-5.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24005-5.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"165 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77750106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24010.X
Deborah A. Farmer, E. Platz, P. Febbo, M. Stampfer, P. Kantoff, E. Giovannucci
Objectives: Rare HRAS1 variable number tandem repeats (VNTR) have been associated with increased risks for a variety of cancers. We investigated the relationship of this polymorphism with the risk of prostate cancer among 240 cases and 481 control subjects in the Health Professionals Follow-up Study.Materials and Methods: The HRAS1 VNTR region of leukocyte DNA was polymerase chain reaction amplified, and fragment lengths were determined by automated fluorescence detection and computer analysis. We estimated the odds ratios (OR) of prostate cancer for rare HRAS1 VNTR from logistic regression models. Four common HRAS1 VNTR alleles were identified about which there was a distribution of rare 28-nucleotide repeat units. There was no difference (p = 0.4) in the prevalence of rare alleles between cases (25.8%) and control subjects (23.7%). Compared to common alleles, the OR for prostate cancer was 1.13 (95% confidence interval 0.87–1.45) for rare alleles.Conclusions: This study suggests that rare HRAS1 VNTRs may not be important in the etiology of prostate cancer.
{"title":"HRAS1 Proto-Oncogene Polymorphism and Prostate Cancer","authors":"Deborah A. Farmer, E. Platz, P. Febbo, M. Stampfer, P. Kantoff, E. Giovannucci","doi":"10.1046/J.1525-1411.2000.24010.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24010.X","url":null,"abstract":"Objectives: Rare HRAS1 variable number tandem repeats (VNTR) have been associated with increased risks for a variety of cancers. We investigated the relationship of this polymorphism with the risk of prostate cancer among 240 cases and 481 control subjects in the Health Professionals Follow-up Study.Materials and Methods: The HRAS1 VNTR region of leukocyte DNA was polymerase chain reaction amplified, and fragment lengths were determined by automated fluorescence detection and computer analysis. We estimated the odds ratios (OR) of prostate cancer for rare HRAS1 VNTR from logistic regression models. Four common HRAS1 VNTR alleles were identified about which there was a distribution of rare 28-nucleotide repeat units. There was no difference (p = 0.4) in the prevalence of rare alleles between cases (25.8%) and control subjects (23.7%). Compared to common alleles, the OR for prostate cancer was 1.13 (95% confidence interval 0.87–1.45) for rare alleles.Conclusions: This study suggests that rare HRAS1 VNTRs may not be important in the etiology of prostate cancer.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"15 1","pages":"211-218"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82042575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24004.X
G. Martorana, A. Bertaccini, S. Viaggi, R. Belleli
Objective: To develop a practical tool for predicting the pathologic stage in prostate cancer. Materials and Methods: Two hundred fifty patients who had had radical prostatectomy were selected from an Italian longitudinal observational study on prostate cancer. Inclusion criteria for selection were the following: a preoperative prostate specific antigen (PSA) value <50 ng/ml; a clinical stage less than or equal to stage T3c (TNM 1992); the availability of the bioptic Gleason score; and the availability of a pathologic specimen obtained during the radical prostatectomy. Pathologic stages were categorized into five levels according to the increasing severity of the illness. Multivariate logistic regression on polythomous ordinal response was performed to obtain a predictive model of disease progression. A set of parallel scale nomographs then was constructed to transfer the predictive model into a new tool, called the “Uro-gramma,” that is able to simplify the practical use of the traditional nomograms. Results: The Gleason score was the factor that influenced the probability of pathologic stage progression the most; PSA and clinical stage were the second and third most significant factors, respectively. Two-way and three-way interactions were tested and were not found to be significant. The confounding effects of age and neoadjuvant hormonal therapy also were tested, and they had no significant influence on the response variable. A logistic regression algorithm then was used to produce a set of nomographs (the Uro-gramma) for the prediction of different pathologic stages using the Gleason score, PSA level, and clinical stage of disease. Conclusion: The predictive model obtained from this Italian study will help physicians and patients in therapeutic decision making. The Uro-gramma provides a new and easier instrument with respect to previous nomograms and multidimensional tables for pathologic stage prediction.
{"title":"An Innovative Tool for Predicting the Pathologic Stage of Prostate Cancer","authors":"G. Martorana, A. Bertaccini, S. Viaggi, R. Belleli","doi":"10.1046/J.1525-1411.2000.24004.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24004.X","url":null,"abstract":"Objective: To develop a practical tool for predicting the pathologic stage in prostate cancer. \u0000 \u0000 \u0000 \u0000Materials and Methods: Two hundred fifty patients who had had radical prostatectomy were selected from an Italian longitudinal observational study on prostate cancer. Inclusion criteria for selection were the following: a preoperative prostate specific antigen (PSA) value <50 ng/ml; a clinical stage less than or equal to stage T3c (TNM 1992); the availability of the bioptic Gleason score; and the availability of a pathologic specimen obtained during the radical prostatectomy. Pathologic stages were categorized into five levels according to the increasing severity of the illness. Multivariate logistic regression on polythomous ordinal response was performed to obtain a predictive model of disease progression. A set of parallel scale nomographs then was constructed to transfer the predictive model into a new tool, called the “Uro-gramma,” that is able to simplify the practical use of the traditional nomograms. \u0000 \u0000 \u0000 \u0000Results: The Gleason score was the factor that influenced the probability of pathologic stage progression the most; PSA and clinical stage were the second and third most significant factors, respectively. Two-way and three-way interactions were tested and were not found to be significant. The confounding effects of age and neoadjuvant hormonal therapy also were tested, and they had no significant influence on the response variable. A logistic regression algorithm then was used to produce a set of nomographs (the Uro-gramma) for the prediction of different pathologic stages using the Gleason score, PSA level, and clinical stage of disease. \u0000 \u0000 \u0000 \u0000Conclusion: The predictive model obtained from this Italian study will help physicians and patients in therapeutic decision making. The Uro-gramma provides a new and easier instrument with respect to previous nomograms and multidimensional tables for pathologic stage prediction.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"79 1","pages":"193-198"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76664445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24008.X
S. Foley
{"title":"Benign Prostatic Hyperplasia‐Related Hematuria and the Effect of Finasteride","authors":"S. Foley","doi":"10.1046/J.1525-1411.2000.24008.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24008.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"3 1","pages":"189-192"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74484283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24005-3.X
G. Bubley
{"title":"Hormones and Diet: Low Insulin-like Growth Factor-1 But Normal Bioavailable Androgens in Vegan Men.","authors":"G. Bubley","doi":"10.1046/J.1525-1411.2000.24005-3.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24005-3.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"149 1","pages":"219-224"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73592508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-01DOI: 10.1046/J.1525-1411.2000.24002.X
M. Rubenstein, P. Guinan
{"title":"A Review of Various Antisense Oligonucleotide Therapeutic Approaches for Prostate Cancer","authors":"M. Rubenstein, P. Guinan","doi":"10.1046/J.1525-1411.2000.24002.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.24002.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"16 1","pages":"179-188"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84172147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-07-01DOI: 10.1046/J.1525-1411.2000.23003.X
M. Soloway, P. Schellhammer, R. Sharifi, N. Block, P. Venner, A. Patterson, M. Sarosdy, N. Vogelzang, Julie Jones Schellenger, G. Kolvenbag
Objectives: We performed an exploratory analysis to determine whether there was a difference between two antiandrogen-plus-luteinizing hormone-releasing hormone analogs (LHRHas) combinations in patients with minimal or extensive disease. Materials and Methods: Data from a prospective, randomized, double-blind study with a median follow-up of 160 weeks were used to perform an exploratory analysis of outcome with 2 combined androgen blockade regimens in 813 advanced prostate cancer patients based on disease status at entry (minimal or extensive disease). A total of 404 patients received bicalutamide plus LHRHa, and 409 patients received flutamide plus LHRHa. Patients were grouped prospectively by “extent of disease” as determined by bone scan: minimal disease was defined as zero to five lesions, while extensive disease was defined as greater than or equal to six lesions. Patients with no lesions on bone scan (0 lesions) had to have at least one measurable nonskeletal metastasis. Results: Patients with minimal disease receiving bicalutamide plus LHRHa demonstrated a trend to longer survival as reflected by a hazard ratio (HR) of 0.79 (95% confidence interval 0.59–1.07), but this was not statistically significant. In the extensive disease group, the effects of bicalutamide plus LHRHa and flutamide plus LHRHa on disease progression and survival were similar (HR 0.96 and 0.90, respectively). Conclusions: Our results are consistent with previously published data demonstrating that patients with stage D2 prostate cancer and minimal disease have a better outcome than patients with extensive disease. In the patients with minimal disease per bone scan, there was a trend toward a benefit for bicalutamide plus LHRHa compared with flutamide plus LHRHa in terms of survival, but not in terms of disease progression.
{"title":"Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone-Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome","authors":"M. Soloway, P. Schellhammer, R. Sharifi, N. Block, P. Venner, A. Patterson, M. Sarosdy, N. Vogelzang, Julie Jones Schellenger, G. Kolvenbag","doi":"10.1046/J.1525-1411.2000.23003.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2000.23003.X","url":null,"abstract":"Objectives: We performed an exploratory analysis to determine whether there was a difference between two antiandrogen-plus-luteinizing hormone-releasing hormone analogs (LHRHas) combinations in patients with minimal or extensive disease. \u0000 \u0000Materials and Methods: Data from a prospective, randomized, double-blind study with a median follow-up of 160 weeks were used to perform an exploratory analysis of outcome with 2 combined androgen blockade regimens in 813 advanced prostate cancer patients based on disease status at entry (minimal or extensive disease). A total of 404 patients received bicalutamide plus LHRHa, and 409 patients received flutamide plus LHRHa. Patients were grouped prospectively by “extent of disease” as determined by bone scan: minimal disease was defined as zero to five lesions, while extensive disease was defined as greater than or equal to six lesions. Patients with no lesions on bone scan (0 lesions) had to have at least one measurable nonskeletal metastasis. \u0000 \u0000Results: Patients with minimal disease receiving bicalutamide plus LHRHa demonstrated a trend to longer survival as reflected by a hazard ratio (HR) of 0.79 (95% confidence interval 0.59–1.07), but this was not statistically significant. In the extensive disease group, the effects of bicalutamide plus LHRHa and flutamide plus LHRHa on disease progression and survival were similar (HR 0.96 and 0.90, respectively). \u0000 \u0000Conclusions: Our results are consistent with previously published data demonstrating that patients with stage D2 prostate cancer and minimal disease have a better outcome than patients with extensive disease. In the patients with minimal disease per bone scan, there was a trend toward a benefit for bicalutamide plus LHRHa compared with flutamide plus LHRHa in terms of survival, but not in terms of disease progression.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"14 1","pages":"137-145"},"PeriodicalIF":0.0,"publicationDate":"2000-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80411859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：